Abstract
The aim of the study was to assess the effects of the combination of metformin plus pioglitazone or rosiglitazone on glucose and blood pressure in type 2 diabetic patients with metabolic syndrome, as well as its tolerability in those patients. In this 12-month, multicentric, double-blind, randomized, controlled, parallel-group trial, all patients began with metformin. Patients were randomized for self-administration of either pioglitazone or rosiglitazone for 12 months. We assessed body mass index (BMI), glycemic control (glycosylated hemoglobin [HbA1c], fasting and postprandial plasma glucose and insulin levels [FPG, PPG, FPI and PPI, respectively] and homeostasis model assessment [HOMA] index) and systolic and diastolic blood pressure (SBP and DBP, respectively), at baseline and at 3, 6, 9 and 12 months of treatment, as well as high-sensitivity C-reactive protein (hs-CRP), nitrites/nitrates and adiponectin (ADN) at baseline and at 12 months of treatment. Significant HbA1c decreases were obtained after 9 (p<0.05) and 12 (p<0.01) months in both groups. After 9 and 12 months, mean FPG and PPG levels were decreased in both groups (p<0.05 and p<0.01, respectively). We observed decreases in FPI and PPI at 9 and 12 months (p<0.05 and p<0.01, respectively) compared to the baseline values in both groups. Furthermore, HOMA index improvement over the baseline value was obtained only at 12 months (p<0.05) in both groups. SBP and DBP improved significantly (p<0.05, for each) in both groups after 12 months. hs-CRP decreased significantly (p<0.05) in both groups after 12 months; nitrites/nitrates and ADN increased significantly (p<0.05, for each) in both groups after 12 months. The combination of thiazolinediones and metformin is associated with a slight but significant improvement in the long-term blood pressure control of these patients, and with an improvement in the anti-inflammatory state, both of which are related to a similar reduction in insulin-resistance.
Similar content being viewed by others
Article PDF
References
Beckman JA, Creager MA, Libby P : Diabetes and atherosclerosis. Epidemiology, Pathophysiology, and Management. JAMA 2002; 287: 2570–2581.
Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman R : Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005; 48: 868–877.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus : American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care 2002; 25 ( Suppl 1): S1–S147.
Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S : Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828–834.
Riddle M : Combining sulfonylureas and other oral agents. Am J Med 2000; 108 ( Suppl 6a): 15S–22S.
Vague P : Is metformin more than an oral hypoglycaemic agent? Diabetes Metab 2003; 29: 6 S5–6S7.
Johnson JA, Simpson SH, Majumdar SR, Toth EL : Decreased mortality associated with the use of metformin compared with sulphanylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244–2248.
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 253: 854–865.
The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
Ovalle F, Ovalle-Berúmen JF : Thiazolidinediones: a review of their benefits and risks. South Med J 2002; 95: 1188–1194.
Charbonnel B, Schernthaner G, Brunetti P, et al: Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093–1104.
Mooradian AD, Chehade J, Thurman JE : The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treat Endocrinol 2002; 1: 13–20.
American Diabetes Association : Screening for diabetes (Position Statement). Diabetes Care 2001; 24 ( Suppl): S21–S24.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults : Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
1999 World Health Organization–International Society of Hypertension Guidelines for the Management of Hypertension : Guidelines Subcommittee. J Hypertens 1999; 17: 151–183.
World Health Organization : Obesity: Preventing and Managing the Global Epidemic. Report of WHO Consultation on Obesity. Geneva, WHO, 1997.
American Diabetes Association : Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001; 24 ( Suppl): S44–S47.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC : Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
Rifai N, Tracy RP, Ridker PM : Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136–2141.
Green LC, Wagner DA, Glogowski L, et al: Analysis of nitrate, nitrite and [15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131–138.
Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941–946.
Winer BJ : Statistical Principles in Experimental Design, 2nd ed. New York, McGraw-Hill, 1971.
Mancia G : The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005; 42 ( Suppl 1): S17–S25.
Boyle PJ, King AB, Olansky L, et al: Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378–396.
Derosa G, Cicero AF, Gaddi A, et al: Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744–754.
Derosa G, Cicero AFG, D'Angelo A, et al: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28: 917–924.
Shargorodsky M, Wainstein G, Gavish E, Leibovitz Z, Matas D, Zimlichman R : Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003; 16: 617–622.
Fullert S, Schneider F, Haak E, et al: Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503–5506.
Granberry MC, Fonseca VA : Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs 2005; 5: 201–209.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Derosa, G., Fogari, E., Cicero, A. et al. Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin. Hypertens Res 30, 387–394 (2007). https://doi.org/10.1291/hypres.30.387
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.387
Keywords
This article is cited by
-
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Cardiovascular Diabetology (2021)
-
Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials
Scientific Reports (2020)
-
The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus
Heart Failure Reviews (2018)
-
Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan
Clinical and Experimental Nephrology (2017)
-
Influence of fibrinogen and C-RP on progression of peripheral arterial disease in type 2 diabetes: a preliminary report
Cardiovascular Diabetology (2013)